APOE and Alzheimer disease: Despite absence of conclusive evidence for the role of the promoter region polymorphisms in AD risk, the transcriptional complexity of APOE and its dual role in the central nervous system (CNS), APOE-directed therapeutics aimed at modifying its levels are advocated for treatment of AD.